子宫输卵管泡沫超声造影能否替代子宫输卵管造影作为输卵管通畅性首选检查?一项随机非劣效性试验
这项在荷兰26家医院开展的多中心前瞻性随机对照研究纳入1026例不孕女性,比较以子宫输卵管泡沫超声造影(HyFoSy)与子宫输卵管造影(HSG)结果为基础的临床管理对妊娠结局的影响。HyFoSy组与HSG组12个月内持续妊娠至活产的估计比例分别为46%与47%(差值-1.2%,95%CI:-3.4%至1.5%),未达到预设-2%的非劣效界值(P=0.27)。HyFoSy的疼痛评分显著低于HSG。
要点
- HyFoSy与HSG在多数患者中产生相似的输卵管通畅性结果。
- 基于HyFoSy或HSG结果的管理,活产率未见统计学显著非劣效。
- HyFoSy的平均疼痛评分显著低于HSG。
核心结论
- HyFoSy与HSG在多数不孕夫妇中产生相似的输卵管病理结果;当两者结果不一致时,这种差异并未导致妊娠结局的实质性差异;同时HyFoSy与显著更轻的疼痛相关。
研究设计与样本
- 荷兰26家医院开展的多中心、前瞻性、随机对照比较研究;纳入18至41岁、在生育检查中计划行输卵管通畅性检查的不孕女性。
- 所有参与女性按随机顺序先后接受HyFoSy和HSG;结果不一致者随机分配至基于HyFoSy结果或基于HSG结果的临床管理策略。
- 主要结局为入组后12个月内持续妊娠至活产,采用意向性分析。
主要发现
- 2015年5月至2019年1月间,1026例女性接受了HyFoSy和HSG检查。
- HyFoSy结果不确定者97例(9.5%),HSG结果不确定者30例(2.9%),两者均不确定者9例(0.9%)。
- 747例女性(73%)两项检查结果一致且确定;143/1026例(14%)结果不一致,其中105例被随机分配至基于HyFoSy或基于HSG结果的管理。
- 在结果不一致的随机组中,分配至HyFoSy管理组的54例女性中22例(41%)实现持续妊娠至活产,分配至HSG管理组的51例女性中25例(49%)实现持续妊娠至活产(差值-8%;95%CI:-27%至10%)。
- 总体上,基于HyFoSy结果的临床管理估计使474/1026例女性(46%)实现活产,基于HSG结果的管理为486/1026例(47%)(差值-1.2%;95%CI:-3.4%至1.5%);相对于预设-2%的界值,未能证明HyFoSy对HSG具有统计学显著的非劣效性(P=0.27)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 由于所有女性均接受了两种输卵管通畅性检查,无法就输卵管通液术的直接治疗效果得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does hysterosalpingo-foam sonography (HyFoSy) lead to similar pregnancy outcomes, compared with hysterosalpingography (HSG), as first-choice tubal patency test in infertile couples? SUMMARY ANSWER: HyFoSy and HSG produce similar findings in a majority of patients and clinical management based on the results of either HyFoSy or HSG, leads to comparable pregnancy outcomes. HyFoSy is experienced as significantly less painful. WHAT IS KNOWN ALREADY: Traditionally, tubal patency testing during fertility work-up is performed by HSG. HyFoSy is an alternative imaging technique lacking ionizing radiation and iodinated contrast medium exposure which is less expensive than HSG. Globally, there is a shift towards the use of office-based diagnostic methods, such as HyFoSy. STUDY DESIGN, SIZE, DURATION: This multicentre, prospective, comparative study with a randomized design was conducted in 26 hospitals in The Netherlands. Participating women underwent both HyFoSy and HSG in randomized order. In case of discordant results, women were randomly allocated to either a management strategy based on HyFoSy or one based on HSG. PARTICIPANTS/MATERIALS, SETTING, METHODS: We included infertile women between 18 and 41 years old who were scheduled for tubal patency testing during their fertility work-up. Women with anovulatory cycles not responding to ovulation induction, endometriosis, severe male infertility or a known iodine contrast allergy were excluded. The primary outcome for the comparison of the HyFoSy- and HSG-based strategies was ongoing pregnancy leading to live birth within 12 months after inclusion in an intention-to-treat analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Between May 2015 and January 2019, 1026 women underwent HyFoSy and HSG. HyFoSy was inconclusive in 97 of them (9.5%), HSG was inconclusive in 30 (2.9%) and both were inconclusive in 9 (0.9%). In 747 women (73%) conclusive tests results were concordant. Of the 143/1026 (14%) with discordant results, 105 were randomized to clinical management based on the results of either HyFoSy or HSG. In this group, 22 of the 54 women (41%) allocated to management based on HyFoSy and 25 of 51 women (49%) allocated to management based on HSG had an ongoing pregnancy leading to live birth (Difference -8%; 95% CI: -27% to 10%). In total, clinical management based on the results of HyFoSy was estimated to lead to a live birth in 474 of 1026 women (46%) versus 486 of 1026 (47%) for management based on HSG (Difference -1.2%; 95% CI: -3.4% to 1.5%). Given the pre-defined margin of -2%, statistically significant non-inferiority of HyFoSy relative to HSG could not be demonstrated (P = 0.27). The mean pain score for HyFoSy on the 1-10 Visual Analogue Scale (VAS) was 3.1 (SD 2.2) and the mean VAS pain score for HSG was 5.4 (SD 2.5; P for difference < 0.001). LIMITATIONS, REASONS FOR CAUTION: Since all women underwent both tubal patency tests, no conclusions on a direct therapeutic effect of tubal flushing could be drawn. WIDER IMPLICATIONS OF THE FINDINGS: HyFoSy or HSG produce similar tubal pathology findings in a majority of infertile couples and, where they differ, a difference in findings does not lead to substantial difference in pregnancy outcome, while HyFoSy is associated with significantly less pain. STUDY FUNDING/COMPETING INTEREST(S): The FOAM study was an investigator-initiated study funded by ZonMw, The Netherlands organization for Health Research and Development (project number 837001504). ZonMw funded the whole project. IQ Medical Ventures provided the ExEm-foam® kits free of charge. The funders had no role in study design, collection, analysis and interpretation of the data. K.D. reports travel and speaker fees from Guerbet. F.J.M.B. reports personal fees as a member of the external advisory board for Merck Serono, The Netherlands, and a research support grant from Merck Serono, outside the submitted work. C.B.L. reports speakers' fee from Ferring in the past, and his department receives research grants from Ferring, Merck and Guerbet. J.S. reports a research agreement with Takeda on MR of motility outside the submitted work. M.V.W. reports leading The Netherlands Satellite of the Cochrane Gynaecology and Fertility Group. B.W.J.M. is supported by an NHMRC Investigator grant (GNT1176437). B.W.J.M. reports consultancy for Guerbet and research funding from Merck and Guerbet. V.M. reports non-financial support from IQ medicals ventures, during the conduct of the study; grants and personal fees from Guerbet, outside the submitted work. The other authors do not report conflicts of interest. TRIAL REGISTRATION NUMBER: NTR4746/NL4587 (https://www.trialregister.nl). TRIAL REGISTRATION DATE: 19 August 2014. DATE OF FIRST PATIENT’S ENROLMENT: 7 May 2015.
引用
- van Welie N, van Rijswijk J, Dreyer K, et al. Can hysterosalpingo-foam sonography replace hysterosalpingography as first-choice tubal patency test? A randomized non-inferiority trial. Hum Reprod. 2022. PMID: 35220432. doi:10.1093/humrep/deac034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。